SUBSCRIBERS
Roche to pay more than US$1b for majority stake in tumour-testing company
Published Mon, Jan 12, 2015 · 09:50 PM
New York
THE Swiss pharmaceutical giant Roche said on Monday that it would acquire a majority of the tumour-testing company Foundation Medicine for more than US$1 billion, in a deal aimed at improving both cancer treatment and drug development.
Foundation is the leader in the growing area of sequencing the genes of tumour samples, looking for mutations that can help predict which drug will be most effective for a particular patient.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Australia’s retail sales volumes fall 0.4% in Q1
Possible class action lawsuit against Cordlife by customers could take at least 2 years
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore